Taken together, the above results indicated that XRCC4 knockdown significantly increased the cisplatin sensitivity by promoting cisplatin-induced DNA damage in the cisplatin-resistant ovarian cancer cells. This evidence concerns the gene XRCC4 and ovarian carcinoma.